ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Bevacizumab biosimilar (Mvasi) 100 mg/40 mL and 400 mg/16 mL concentrate for solution for infusion in line with its registered indications or local clinical protocols for treating:
    • Persistent, recurrent, or metastatic cervical cancer when used with platinum-based chemotherapy plus paclitaxel;
    • Metastatic colorectal cancer when used with fluoropyrimidine-based chemotherapy;
    • Malignant glioma (WHO Grade III and IV) after relapse or disease progression following prior therapy;
    • Previously untreated, unresectable, locally advanced, recurrent or metastatic non-squamous non-small-cell lung cancer when used with carboplatin and paclitaxel;
    • Previously untreated, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have suboptimally debulked Stage III disease with more than 1 cm of residual disease or Stage III unresectable or Stage IV disease;
    • Recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer when used with carboplatin and gemcitabine or paclitaxel;
    • Recurrent, platinum-resistant, epithelial ovarian, fallopian tube, or primary peritoneal cancer when used with paclitaxel, topotecan or pegylated liposomal doxorubicin; and
    • Advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer as maintenance treatment in combination with olaparib in adults who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar.

Subsidy status

Bevacizumab biosimilar (Mvasi) 100 mg/4 mL and 400 mg/16 mL concentrate for solution for infusion are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications with effect from 1 April 2022.

SDL subsidy does not apply to any formulations or strengths of bevacizumab reference biologic (Avastin) or other brands of bevacizumab biosimilars.

Clinical indications, subsidy class and MediShield Life claim limits are provided in the Annex.


Bevacizumab biosimilar for treating different types of cancer (12 Jul 22) Bevacizumab biosimilar for treating different types of cancer PES (1 Apr 2022)